v3.24.3
Consolidated Balance Sheets (Unaudited) - USD ($)
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 4,153,592 $ 1,123,604
Unbilled receivable 1,782,805 97,561
Prepaid expenses and other current assets 3,154,110 1,067,703
Total current assets 9,090,507 2,288,868
Other assets 294,217 419,217
Total assets 9,384,724 2,708,085
Current liabilities:    
Accounts payable 1,967,573 1,936,007
Accrued expenses and other liabilities 447,035 542,260
Notes payable and accrued interest 387,176 854,697
Total current liabilities 2,801,784 3,332,964
Long-term liabilities:    
Liability classified warrants 3,213 26,388
Total long-term liabilities 3,213 26,388
Total liabilities 2,804,997 3,359,352
Commitments and contingencies (Note 6)
Stockholders’ equity (deficit)    
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at September 30, 2024 (unaudited) and December 31, 2023
Common stock, $0.0001 par value, 250,000,000 shares authorized at September 30, 2024 (unaudited) and December 31, 2023; 13,870,591 and 3,146,157 shares issued at September 30, 2024 (unaudited) and December 31, 2023, respectively; 13,870,510 and 3,146,076 shares outstanding at September 30, 2024 (unaudited) and December 31, 2023, respectively 1,387 315
Additional paid-in capital 132,886,700 121,233,901
Accumulated deficit (125,979,877) (121,557,074)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit) 6,908,210 (322,858)
Noncontrolling interests in stockholders’ deficit (328,483) (328,409)
Total stockholders’ equity (deficit) 6,579,727 (651,267)
Total liabilities and stockholders’ equity (deficit) $ 9,384,724 $ 2,708,085

Source

PDF HTML
ZIP XLS XBRL